Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo.

BACKGROUND Genetic findings suggesting a lower susceptibility to melanoma in patients with vitiligo are supported by recent clinical studies. Nonmelanoma skin cancer (NMSC) has also been studied, but mainly in small samples, and with conflicting results. OBJECTIVE We sought to study the relative risk (RR) of melanoma and NMSC in patients with vitiligo compared with that in patients seen for vascular surgery. METHODS The frequency of melanoma and NMSC was compared between patients with vitiligo and patients seen for vascular surgery. Occurrence of skin cancer was compared by computing RR and modeled using multiple logistic regression. RESULTS Overall, the crude RR for melanoma was 0.24 (95% confidence interval [CI] 0.13-0.45) in patients with vitiligo compared with those with a nondermatologic condition (occurrence 1.1‰, 95% CI 0.5‰-2.0‰ in patients with vitiligo and occurrence 4.5‰, 95% CI 3.8‰-5.4‰ in the control cohort). The crude RR for NMSC was 0.19 (95% CI 0.14-0.17) and the occurrence was 3.8‰ (95% CI 2.7‰-5.2‰) among patients with vitiligo and 19.6‰ (95% CI 18.0‰-21.4‰) in control subjects. Patients with vitiligo who underwent phototherapy had a markedly higher risk of both cancers. CONCLUSIONS In our large study, patients with vitiligo have a decreased risk of developing skin neoplasms, even considering that a larger proportion in this patient group is exposed to higher levels of ultraviolet radiation.

[1]  K. thestrup-pedersen,et al.  PUVA treatment of vitiligo: a retrospective study of 59 patients. , 1992, Acta dermato-venereologica.

[2]  N. Balato,et al.  Psoriasis and melanocytic naevi: does the first confer a protective role against melanocyte progression to naevi? , 2011, The British journal of dermatology.

[3]  R. Halder,et al.  Cutaneous malignancies in patients treated with psoralen photochemotherapy (PUVA) for vitiligo. , 1995, Archives of dermatology.

[4]  J. Naeyaert,et al.  Evidence for an autoimmune pathogenesis of vitiligo. , 2003, Pigment cell research.

[5]  R. Stern,et al.  High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients. , 2005, The Journal of investigative dermatology.

[6]  B. Leppard,et al.  Actinic damage and skin cancer in albinos in northern Tanzania: findings in 164 patients enrolled in an outreach skin care program. , 1995, Journal of the American Academy of Dermatology.

[7]  K. Schallreuter,et al.  Enhanced DNA binding capacity on up‐regulated epidermal wild‐type p53 in vitiligo by H2O2‐mediated oxidation: a possible repair mechanism for DNA damage , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  C. Hexsel,et al.  Current sunscreen issues: 2007 Food and Drug Administration sunscreen labelling recommendations and combination sunscreen/insect repellent products. , 2008, Journal of the American Academy of Dermatology.

[9]  S. Picksley,et al.  Increased epidermal functioning wild‐type p53 expression in vitiligo , 2003, Experimental dermatology.

[10]  Jo Lambert,et al.  Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. , 2010, The New England journal of medicine.

[11]  T. Nijsten,et al.  Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners , 2013, The British journal of dermatology.

[12]  M. Picardo,et al.  Clinical practice. Vitiligo. , 2009, The New England journal of medicine.

[13]  D. Abeni,et al.  Clustering of Cutaneous Melanoma in Health Care Workers of a Dermatological Day Hospital Unit , 2014, Dermatology.

[14]  J. Malvehy,et al.  Genome-wide association study identifies three loci associated with melanoma risk , 2009, Nature Genetics.

[15]  A. Feily,et al.  Why vitiligo is associated with fewer risk of skin cancer? Providing a molecular mechanism , 2011, Archives of Dermatological Research.

[16]  R. Stern.  The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. , 2012, Journal of the American Academy of Dermatology.

[17]  M. Szklo,et al.  Epidemiology: Beyond the Basics , 1999 .

[18]  D. Tobin,et al.  Decreased Photodamage and Low Incidence of Non-Melanoma Skin Cancer in 136 Sun-Exposed Caucasian Patients with Vitiligo , 2002, Dermatology.

[19]  C. Johnson,et al.  Incidence of nonmelanoma skin cancer in a cohort of patients with vitiligo. , 2009, Journal of the American Academy of Dermatology.

[20]  R. Stern.  Malignant melanoma in patients treated for psoriasis with PUVA , 1999, Photodermatology, photoimmunology & photomedicine.

[21]  A. Necker,et al.  Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. , 2001, The Journal of investigative dermatology.

[22]  J. Kirkwood,et al.  Prognostic significance of autoimmunity during treatment of melanoma with interferon , 2006, Seminars in Immunopathology.

[23]  M. Fredrikson,et al.  Low risk of melanoma in patients with atopic dermatitis , 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.

[24]  R. Brodell,et al.  A male infant with anhidrotic ectodermal dysplasia/immunodeficiency accompanied by incontinentia pigmenti and a mutation in the NEMO pathway. , 2008, Journal of the American Academy of Dermatology.

[25]  E. Frenk,et al.  Long-term actinic damage in sun-exposed vitiligo and normally pigmented skin. , 1987, Dermatologica.

[26]  G. Ogg,et al.  High Frequency of Skin-homing Melanocyte-specific Cytotoxic T Lymphocytes in Autoimmune Vitiligo , 1998, The Journal of experimental medicine.

[27]  C. Melief,et al.  Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. , 2009, The Journal of investigative dermatology.